ホーム>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>BRD0639

BRD0639

カタログ番号GC63731

BRD0639 は、PRMT5 基質アダプター相互作用のクラス初の阻害剤です。 BRD0639 は、PBM 依存性 PRMT5 活性の研究をサポートできる PRMT5 結合モチーフ (PBM) 競合剤です。

Products are for research use only. Not for human use. We do not sell to patients.

BRD0639 化学構造

Cas No.: 2760881-74-9

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$141.00
在庫あり
5 mg
$135.00
在庫あり
10 mg
$225.00
在庫あり
25 mg
$450.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities[1].

BRD0639 is a first-in-class PBM-competitive small molecule that can support studies of PBM dependent PRMT5 activities and the development of novel PRMT5 inhibitors that selectively target these functions. BRD0639 can engage the cellular target and effectively outcompete binding between full-length PRMT5 and RIOK1 proteins with an IC50 of 7.5 uM and 16 uM in permeabilized and living cells, respectively. BRD0639 reduces SDMA in the same subset of proteins also affected by genetic perturbation of the PRMT5 binding motif (PBM) binding site[1].

[1]. McKinney DC, et al. Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction. J Med Chem. 2021;64(15):11148-11168.

レビュー

Review for BRD0639

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BRD0639

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.